Latest Innovation News

NRW Holdings reported robust FY25 results with $3.3 billion revenue and $207.9 million underlying EBITA, boosted by strategic acquisitions including Fredon Industries. The company raised its FY26 guidance, projecting revenue near $4.1 billion and EBITA between $260 million and $265 million, underpinned by a $20.9 billion project pipeline.

ReNerve Ltd reports a strong 53% year-on-year revenue increase, expanding its US distribution network and advancing clinical studies for its nerve repair products. The company is poised for significant global market growth with new partnerships and upcoming product launches.

Axel REE Limited reveals a substantial inferred resource at its Caladão Project, advancing plans for in situ recovery trial mining in 2026 to produce rare earth and gallium products. The company’s low-cost, environmentally conscious approach positions it well within Brazil’s Lithium Valley mining hub.

Minbos Resources is advancing its Cabinda Phosphate and Capanda Green Ammonia projects with secured financing and construction underway, targeting first shipments in the first half of 2026. Strategic partnerships and government support underpin its ambitious plans to boost Angola’s agricultural and export sectors.

Anteris Technologies Global Corp. has filed a Form S-1 registration statement with the SEC to enable resale of shares issued in a recent private placement, marking a key step in advancing its DurAVR transcatheter heart valve system and pivotal clinical trials.

Imugene Limited and JW Therapeutics have launched a strategic collaboration to combine oncolytic virus and CAR-T cell therapies, aiming to tackle refractory solid tumors through a pioneering 'mark and kill' approach.

HUB24 Limited showcased strong growth and strategic innovation at its 2025 Investor Strategy Day, highlighting market leadership and ambitious expansion plans across wealth management technology.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

Race Oncology has received a $2.8 million Australian R&D tax refund for FY2025, with further overseas R&D rebates expected, bolstering its clinical development of innovative cancer therapies.

3D Energi has confirmed a promising gas-condensate find at the Essington-1 well using innovative Ora formation testing, marking the technology's Australian debut and setting the stage for further exploration in the Otway Basin.

Retail Food Group Limited demonstrated resilience in FY25 with slight sales growth and strategic expansions, setting a positive tone for FY26. Key brand innovations and franchisee support underpin its growth trajectory amid leadership transition.

Advanced Innergy Holdings Ltd (ASX, AIH) reported unaudited proforma FY25 results exceeding prospectus forecasts, driven by strong organic growth and the strategic acquisition of Ovun. The company reaffirms its FY26 guidance, supported by a robust orderbook and pipeline.